Qualifying Therapeutic Discovery Project Grants for the State of Florida
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| .Decimal Inc. | Development and Commercialization of Electron Conformal Therapy Bolos | $ 144,260.68 | $ 77,112.17 |
| Accentia Biopharmaceuticals Inc | Revimmune ReBOOT for the treatment of Multiple Sclerosis | $ 75,187.50 | $ 169,291.75 |
| Accu-Break Pharmaceuticals Inc and Subsidiaries | Accu-Break Wafarin | $ 244,479.25 | |
| Adhaere Pharmaceuticals Inc | Novel therapeutic strategies for preserving vascular access graft in hemodialysis patients | $ 45,390.00 | |
| Altor Bioscience Corporation | Altor QTD Project #5 - Development of IL-15 Superagonists for Cancer | $ 1,631.65 | $ 132,923.11 |
| Altor Bioscience Corporation | Altor QTD Project #2 - Development of ALT-802 for Cancer | $ 163,352.23 | $ 81,127.01 |
| Altor Bioscience Corporation | Altor QTD Project #1- Development of ALT-801 for Cancer | $ 244,479.24 | |
| Altor Bioscience Corporation | Altor QTD Project #6 - Development of DPC-1528, an Antisense Drug for Acne | $ 171,144.86 | $ 19,428.32 |
| Altor Bioscience Corporation | ALtor QTD Project #3 - Development of ALT-836 for ALI/ARDS | $ 60,512.03 | |
| AOI Medical Inc | Ascendx Spine Technology | $ 244,479.25 | |
| Applied Genetic Technologies Corp | Alpha One Trial | $ 244,479.25 | |
| Applied Genetic Technologies Corp | Achromatopsia Project | $ 244,479.25 | |
| Applied Genetic Technologies Corporation | XLRS Project | $ 7,446.74 | $ 237,032.51 |
| Applied Genetic Technologies Corporation | LCA Trial | $ 188,664.43 | $ 55,814.82 |
| Aquatrove Biosciences Inc | Novel stratefies for the treatment of vaginal dryness in trying to conceive patients | $ 33,506.00 | $ 95,000.00 |
| Aspiration Medical Technology LLC | FoodDivurzn (FD) Weight Management System | $ 244,479.24 | |
| Atlas Spine, Inc. | APELO | $ 244,479.24 | |
| Banyan Biomarkers, Inc. | Biomarkers of Brain Injury: Magnitude, Secondary Insults and Outcome | $ 244,479.25 | |
| Bioheart, Inc. | MARVEL Trial REGEN Trial | $ 244,479.24 | |
| Bio-Nucleonics Inc | Novel Peptidomimetic for Unstable Atherosclertic Plague detection and differentiation. | $ 244,479.24 | |
| Bio-Nucleonics Inc | Rubidium | $ 244,479.25 | |
| Bio-Nucleonics, Inc. | Gallium-68/Germanium-68 Radionuclide Generator | $ 244,479.25 | |
| Bio-Nucleonics, Inc. | Gynocyte | $ 244,479.25 | |
| Biovest International Inc. | BiovaxID - a patient-specific vaccine for B-cell Non-Hodgkin's Lymphoma | $ 244,479.25 | |
| Catalyst Pharmaceutical Partners, Inc | CPP-109 For The Treatment Of Stimulant Dependence | $ 244,479.24 | |
| Catalyst Pharmaceutical Partners, Inc | CPP-115 for the treatment of various forms of Epilepsy and stimulant dependence | $ 110,454.66 | $ 134,024.58 |
| CHS RESOURCES, LLC | TOPICAL TREATMENT FOR SKIN CANCER AND OTHER PRE-CANCEROUS CONDITIONS. | $ 60,442.50 | $ 184,036.75 |
| Claro Scientific, LLC | SpectraWave Blood and Blood Culture Diagnostic System | $ 244,479.25 | |
| Concordia Pharmaceuticals, Inc. | Salirasib | $ 244,479.24 | |
| Converge Biotech Inc | Biohybrid Device for Treatment of Diabetes | $ 94,570.00 | $ 84,932.00 |
| Convergent Engineering | eToco Maternal Fetal Monitoring | $ 25,162.00 | $ 9,564.50 |
| Convergent Engineering Inc. | ID-Cap | $ 28,385.50 | |
| CORD:USE Cord Blood Bank, Inc | Allogeneic Cord Blood Banking | $ 244,479.25 | |
| Cytorex Biosciences, Inc. | Cytoreg® | $ 244,479.25 | |
| Dharma Biomedical, LLC | Isolation and Synthesis of Bioactive Molecules from Commiphora wightii Bark Oleoresin | $ 48,612.54 | $ 52,025.56 |
| Electrostim Medical Services Inc. dba EMSI | Iglucotouch | $ 244,479.24 | |
| EnCor Biotechnology Inc. | Development of diagnostic biomarkers of CNS damage and disease states | $ 85,303.50 | $ 159,175.75 |
| Envoy Therapeutics, Inc | A New Oral Therapy for Treating Cognitive Deficts Associated with Schizophrenia | $ 10,827.50 | $ 233,651.75 |
| Envoy Therapeutics, Inc. | A Novel, Non Dopamine-Based oral Therapy for Parkinson's Disease | $ 20,437.50 | $ 224,041.75 |
| Envoy Therapeutics, Inc. | An Oral Therapy for Parkinson's Disease designed to mimic Deep Brain Stimulation | $ 20,437.50 | $ 224,041.75 |
| eTect LLC | ID Cap | $ 21,539.06 | $ 173,403.94 |
| Eyetech Inc | The Macugen ER Project | $ 141,639.50 | $ 102,839.74 |
| Florida Cancer Care Network, LLC | Radiation Therapy Oncology management Program | $ 244,479.25 | |
| GeneEx, Inc | A Rapid Point-of-Care Diagnostic for Active Periodontal Disease | $ 244,479.25 | |
| GeneEx, Inc | A Rapid Point-of-Care Diagnostic for Active Group A Streptococcal Pharyngitis | $ 244,479.25 | |
| GeNO LLC | A ultra-pure inhalede Nitric Oxide drug for chronic treatment of mutiple pulmonary diseases for unmet medical needs | $ 244,479.24 | |
| GlG Pharma LLC | GLG-202 Manufacturing and IND-Enabling Pre-Clinical Toxicology Studies | $ 244,479.25 | |
| GLG Pharma LLC | GLG-401 Manufacturing and IND-Enabling Pre-clinical Toxicology Studies | $ 244,479.25 | |
| GLG Pharma, LLC | GLG-302 Manufacturing and IND-Enabling Pre-Clincal Toxicology Studies | $ 244,479.24 | |
| Heat Biologics Inc | HS-System | $ 82,044.68 | $ 162,434.56 |
| Imigene Inc | High Clinical Relevancy Point of Care Blood Borne Bacteria Detection | $ 91,800.00 | $ 152,679.25 |
| InnFocus | a Novel Drug/Medical Device Treatment for Glaucoma | $ 244,479.24 | |
| Intezyne Technologies, Inc | Polymer Polyplex | $ 52,231.88 | $ 43,059.02 |
| Intezyne Technologies, Inc | Ivect Technology | $ 244,479.24 | |
| iSense, LLC | Colorimetric Breath Analyzer for Lung Cancer Diagnosis | $ 156,605.83 | $ 87,873.42 |
| Ivax Diagnostics, Inc. | Mago4S and diagnostic ELISA and IFA assays | $ 244,479.25 | |
| LifeSync Corporation | WECGII | $ 244,479.25 | |
| LINGUAFLEX, INC | LINGUAFLEX TONGUE RETRACTOR (LTR) | $ 244,479.24 | |
| Mergenet Medical, Inc | HiFLO HFT with Airway Pressure Monitoring | $ 200,174.50 | $ 44,304.74 |
| Metabogenix Technologies, Inc | Combining inhibitors of glycolysis with cancer chemotherapy to increase treatment efficacy | $ 244,479.25 | |
| Metabogenix Technologies, Inc. | Fenofibrate induces endoplasmic reticulum stress leading to selective toxicity in multiple myeloma cells | $ 244,479.25 | |
| Morphogenesis, Inc | ImmuneFx ™ Cancer immunotherapy | $ 161,560.50 | $ 82,918.74 |
| Nanotherapeutics Inc | NanoDOX 1% Doxycycline Monohydrate Hydrogel for the treatment of Chronic Wounds | $ 91,995.13 | $ 98,718.24 |
| Nanotherapeutics, Inc. | NanoBUP Buprenorphine/Naloxone Capsule for the Treatment of Opiod Addiction | $ 74,617.68 | $ 169,861.57 |
| Nanotherapeutics, Inc. | NanoFOVIRTM Inhaled Cidofovir Dry-Powder Formulation for Postexposure | $ 244,479.25 | |
| Nanotherapeutics, Inc. | NonoGENT™ Gentamicin Sulfate Inhalation Powder for post-exposure prophylaxix of pneumonic plague (Yersinia pestis) | $ 244,479.25 | |
| NeoGenomics Inc | Melanoma FISH Test | $ 244,479.24 | |
| NeoGenomics Laboratories Inc | Barrett's esophagus FISH Test | $ 130,000.00 | |
| Neuro Assisted Recovery Inc | NTMD for treatment of Comorbid Substance abuse disorders | $ 234,715.00 | $ 9,764.25 |
| Nutra Pharma Corporation | Development of Recet for the treatment of pain | $ 244,479.25 | |
| Ocean Ridge Biosciences, LLC | Serum MicroRNAs as Prognostic Markers of Emphysema | $ 34,873.00 | $ 34,562.00 |
| OPKO Instrumentation, LLC a single member LLC of OPKO Health, Inc | Aquashunt | $ 244,479.25 | |
| OPKO Pharmaceuticals LLC | Rolapitant | $ 244,479.25 | |
| OPKO Pharmaceuticals LLC a single member LLC of OPKO Health, Inc | Bevasiranib | $ 244,479.25 | |
| Optima Neuroscience, Inc. | High Performance Automated Seizure Detection | $ 244,479.25 | |
| Oragenics Inc | Novel Antibiotics for the Treatment of Healthcare Associated Infections | $ 132,041.27 | $ 112,437.97 |
| Oragenics, Inc | Rapid and Sensitive Id. Of Novel Diagnostic Biomarkers for Cancer for Cancer and Infectious Diseases | $ 186,971.87 | $ 57,507.37 |
| Oragenics, Inc | Prevention of Tooth Decay using SMaRT Replacement Therapy | $ 52,206.00 | $ 192,273.24 |
| Orbus Neich Medical, Inc | Combo Bio-engineered Sirolimus-eluting Stent (Combo Stent) | $ 244,479.24 | |
| OxThera, Inc | Development of Oxabact(R) for the Treatment of Primary Hyperoxaluria | $ 244,479.24 | |
| ParinGenix, Inc. | Prevention of heparin-induced thrombocytopenia and associated thrombosis | $ 26,693.00 | $ 125,648.00 |
| ParinGenix, Inc. | Development of a treatment of pediatric protein-losing enteropathy | $ 19,938.50 | $ 204,564.50 |
| Pioma Inc | TAME-DX: A blood based diagnostic for evidence-based treatment of brain cancer. | $ 63,885.00 | $ 180,594.25 |
| Precision Medical Devices, Inc | Flow Control Device | $ 105,038.00 | $ 139,441.25 |
| Quantum Immunologics Inc | Development of Oncofetal Antigen/immature Laminin Receptor Protein (OFA/iLRP) peptides for the treatment of cancer | $ 66,922.72 | $ 137,628.09 |
| Quantum Immunologics Inc | A Phase I/II Study with Autologous Dendritic Cells Loaded with Oncofetal Antigen/iL RP in Patients with Metastatic Breast Cancer | $ 244,479.25 | |
| Quantum Immunologics, Inc | Developmental of Monoclonal Antibodies against OFA/ILRP | $ 59,506.57 | $ 137,628.09 |
| Quick-Med Technologies, Inc | NIMBUS Wound Dressings/Drain (DWD) | $ 244,479.25 | |
| SafeStitch Medical, Inc. and Subsidiaries | AMID Stapler for Simplified Stapled Lichtenstein Procedure (SSLP) | $ 244,479.25 | |
| Seraph Pharmaceuticals | Ketogenic diet in a pill with antioxidant activity for control of epileptic seizures | $ 10,750.00 | $ 35,000.00 |
| Sinapis Pharma Inc | IV Methamphetamine for Stroke and other acute ischemic conditions | $ 186,112.00 | $ 58,367.24 |
| SKELETAL DYNAMICS LLC | INTERNAL JOINT STABILIZER FOR THE ELBOW | $ 134,395.88 | $ 110,083.36 |
| Skeletal Dynamics LLC | Align Radial Head Arthroplasty System | $ 152,094.98 | $ 92,384.26 |
| Syntheon LLC | Milwaukee Project | $ 244,479.25 | |
| TauTaTis, Inc | Evaluation of the kinase inhibitor TTT-3002 for neurodegenerative diseases and cancer | $ 109,391.50 | $ 135,087.74 |
| Tele Home Care Solutions Company | The Tele Home Care Solution Project | $ 152,410.83 | |
| Tigris Pharmaceuticals, Inc | AFP-464 | $ 244,479.25 | |
| Tigris Pharmaceuticals, Inc. | GGTI-2418 | $ 244,479.25 | |
| Tissue Tech, Inc | Treatment for Demodex Infestation by Active Ingredient from Tea Tree Oil | $ 31,783.50 | $ 162,450.50 |
| Tissue Tech, Inc | Novel Therapeutics based on Amniotic Membrane Extract and its Purified Component | $ 164,862.00 | $ 79,617.25 |
| Tissue Tech,Inc | development of a Novel Device to deliver Therapeutics to Ocular Surface | $ 51,019.50 | $ 90,106.00 |
| Tissuetech,Inc | Novel Ex Vivo Expansion of Limbal stem Cells | $ 189,002.50 | $ 55,476.75 |
| Tyrogenex Inc | X-82 VEGFR/PDGFR small molecule kinase inhibitor | $ 155,311.00 | $ 89,168.25 |
| Venx LLC | Device Strategies for the management of Venous Stasis | $ 39,549.00 | $ 165,950.50 |
| Winprobe Corporation | The Ultravision Research Project | $ 244,479.25 | |
| Xcelience | SKL-10406 | $ 61,698.47 | $ 17,564.24 |
| Xcelience Holdings LLC | PX-866 | $ 39,831.05 | $ 27,468.85 |
| Xcelience Holdings LLC | CTO | $ 18,562.47 | $ 7,738.27 |
| Xcelience Holdings, LLC | DAS-181 | $ 21,073.91 | $ 54,300.04 |
| Xcelience Holdings, LLC | AM-152 | $ 53,076.00 | |
| Xcelience Holdings, LLC | CC-930 | $ 156,629.47 | $ 87,849.78 |
| Xcelience Holdings, LLC | AT-406 | $ 26,236.82 | $ 13,418.48 |
| Xcelience Holdings, LLC | OSI-296 | $ 50,273.75 | $ 28,662.85 |
| Xcelience Holdings, LLC | Acuracet | $ 165,781.99 | $ 78,697.26 |
| Xcelience Holdings, LLC | Duodopa | $ 22,118.87 | |
| Xcelience Holdings, LLC | AP24534 | $ 52,264.27 | $ 192,214.98 |
| Xcelience Holdings, LLC | Alpha-tocherolquinone | $ 60,602.00 | $ 183,877.25 |
| Xcelience Holdings, LLC | Loperamide | $ 69,003.32 | $ 54,202.23 |
| Xcellience Holdings, LLC | PN-3602 | $ 89,974.23 | $ 143,487.74 |
| Xcovery Holding Company LLC | X-379 c-Met small molecule kinase inhibitor | $ 35,661.50 | $ 208,817.75 |
| Xcovery Holding Company LLC | x-387 mTor (TORC1/TORC2) small molecule kinase inhibitor | $ 177,961.50 | $ 66,517.75 |
| Xcovery Holding Company LLC | X-396 (ALK) small molecule kinase inhibitor | $ 41,638.00 | $ 202,841.25 |
| Xhale diagnostics, Inc | One Breath: a non-invasive glucose self-monitoring system using exhaled breath | $ 244,479.25 | |
| Xhale, Inc. | Next generation evidential breath-based ethanol sensor to diagnose and treat alcohol abuse | $ 69,604.00 | $ 108,888.00 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
